they would like but 0% response is unusual and there may be something wrong with results data, the tests were carried out in corrupt countries like India, Ukraine etc.
Money talks, #$%$ walks.if they have confidence in the data, the way to allay concerns expressed by AF or anyone is if all the directors buy shares in the open market now. They gotta put down hard cash on the table.
I own a few shares in CYRX and I believe AF's article was great and raised a lot of good points including how the non executive awarded themselves stock ahead of the news. The SEC needs to probe that alone and there should be a closed period to trade shares etc ahead of such important news.
As a investor I also want to hear what the company has to say about the clinical trial issues raised by AF. Nothing less than a detailed rebuttal will satisfy the market or me. AF is only doing the job that regulators should be doing.
the company may be planning to raise some more cash, which is why the analysts have been holding off saying anything. always happens like that. new money gets raised soon after good clinical tests.
there is no cast iron rule that is guaranteed to work. Its also based on experience but analysing charts (technical analysis) can also help. You will see that the reent highs over 2 years has been around $5m. If you believe that the recent news big and that share price has moved up with high volumes that it may mark a sea-change in investors perceptions about the stock. As recent the share price is likely to run up to the recent highs of $5. at that point you may have a chance to review your next step. It is decisivey breaks out from the previous high it may have more room to gain.
Secondly fundamentals can also help. The company has a low enterprise value relative to the potential revenues of the new drug (if approved). so it looks attractive to buy into despite the recent run up.
anyway that is my thought on it. Good luck!
just a stupid question: if these people in the trial had already run out of treatment options and therefore already on death row, does it matter if there is high proportion of fatalities. the survival rate and duration is still worthwhile, no?
answers please. Also please note the shares afre bouncing off 50 DMA line. Bullish if its staus above it as it shows support around curren levels.
H anyone know a specific reason why the stock is so strong lately other than the Piper target of $61? Something must be going on. Does anyone have access to the Piper note, please post the summary if so. tnx
The shares have broken to a new high on good volumes. This is bullish and with analysts upgrading their price targets its heading higher in the short term anyway. $60 looks achieveable by end of Oct.